HAHaemonetics HAE · NYSE
$118.76 +0.41% (+$0.48)
- Market cap
- $5.40B
- Enterprise value
- $6.35B
- P/E
- 56.1x
- Forward P/E
- 21.4x
- PEG
- 0.8x
- P/S
- 4.0x
- P/FCF
- 18.6x
- EV/EBITDA
- 24.3x
- ROIC
- 8.6%
- Gross margin
- 57.4%
- Net margin
- 7.1%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 3.6x
- Beta
- 0.54
- Free float
- 98.7%
About the company
Haemonetics Corporation is an American company specializing in the development and manufacturing of medical technologies focused on blood product processing. Founded in 1971, the company’s primary focus is on innovations in blood transfusion, blood component separation, and patient monitoring. Haemonetics provides products and solutions for hospitals, blood banks, and transfusion centers that help optimize the processes of blood donation and usage, while ensuring safety and treatment efficiency. The company is known for its advanced devices and systems for separating plasma, red blood cells, and platelets, ensuring precision and quality in handling blood products.
Sector
Healthcare
Industry
Medical - Devices
CEO
Christopher A. Simon
Employees
3,009
Headquarters
Boston
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number